Toxicological Research

Korean Society of Toxicology & Korea Environmental Mutagen Society (한국독성학회)
권호 표지
DOI QR코드

DOI QR Code

Semi-automated approach for generation of biological networks on drug-induced cholestasis, steatosis, hepatitis, and cirrhosis

  • Received : 2021.12.09
  • Accepted : 2022.02.11
  • Published : 2022.07.15
⟨ Previous Next ⟩

Abstract

Drug-induced liver injury (DILI) is one of the leading reasons for discontinuation of a new drug development project. Diverse machine learning or deep learning models have been developed to predict DILI. However, these models have not provided an adequate understanding of the mechanisms leading to DILI. The development of safer drugs requires novel computational approaches that enable the prompt understanding of the mechanism of DILI. In this study, the mechanisms leading to the development of cholestasis, steatosis, hepatitis, and cirrhosis were explored using a semi-automated approach for data gathering and associations. Diverse data from ToxCast, Comparative Toxicogenomic Database (CTD), Reactome, and Open TG-GATEs on reference molecules leading to the development of the respective diseases were extracted. The data were used to create biological networks of the four diseases. As expected, the four networks had several common pathways, and a joint DILI network was assembled. Such biological networks could be used in drug discovery to identify possible molecules of concern as they provide a better understanding of the disease-specific key events. The events can be target-tested to provide indications for potential DILI effects.

Keywords

Acknowledgement

This study was supported by the National Research Foundation of Korea (NRF) funded by the Korean government (NRF-2019R1F1A1061955), and by the Korea Institute of Toxicology (KIT), Republic of Korea (1711133838).

References

  1. Silbergeld EK, Mandrioli D, Cranor CF (2015) Regulating chemicals: law, science, and the unbearable burdens of regulation. Annu Rev Public Health 36:175-191. https://doi.org/10.1146/annurevpublhealth-031914-122654
  2. Van Norman GA (2019) Limitations of animal studies for predicting toxicity in clinical trials: is it time to rethink our current approach? JACC Basic Transl Sci 4:845-854. https://doi.org/10.1016/j.jacbts.2019.10.008
  3. Vall A, Sabnis Y, Shi J, Class R, Hochreiter S, Klambauer G (2021) The promise of AI for DILI prediction. Front Artif Intell 4:638410. https://doi.org/10.3389/frai.2021.638410
  4. Rudin C (2019) Stop explaining black box machine learning models for high stakes decisions and use interpretable models instead. Nat Mach Intell 1:206-215. https://doi.org/10.1038/s42256-019-0048-x
  5. Vinken M (2013) The adverse outcome pathway concept: a pragmatic tool in toxicology. Toxicology 312:158-165. https://doi.org/10.1016/j.tox.2013.08.011
  6. Villeneuve DL, Crump D, Garcia-Reyero N, Hecker M, Hutchinson TH, LaLone CA, Landesmann B, Lettieri T, Munn S, Nepelska M, Ottinger MA, Vergauwen L, Whelan M (2014) Adverse outcome pathway (AOP) development I: strategies and principles. Toxicol Sci 142:312-320. https://doi.org/10.1093/toxsci/kfu199
  7. Hardt C, Bauer C, Schuchhardt J, Herwig R (2018) Computational network analysis for drug toxicity prediction. In: von Stechow L, Santos Delgado A (eds) Computational cell biology: methods and protocols. Springer New York, New York, pp 335-355. https://doi.org/10.1007/978-1-4939-8618-7_16
  8. Rim KT (2021) Application of the adverse outcome pathway framework to predict the toxicity of chemicals in the semiconductor manufacturing industry. Mol Cell Toxicol 17:325-345. https://doi.org/10.1007/s13273-021-00139-4
  9. Doktorova TY, Oki NO, Mohoric T, Exner TE, Hardy B (2020) A semi-automated workflow for adverse outcome pathway hypothesis generation: the use case of non-genotoxic induced hepatocellular carcinoma. Regul Toxicol Pharmacol 114:104652. https://doi.org/10.1016/j.yrtph.2020.104652
  10. Igarashi Y, Nakatsu N, Yamashita T, Ono A, Ohno Y, Urushidani T, Yamada H (2015) Open TG-GATEs: a large-scale toxicogenomics database. Nucleic Acids Res 43:D921-D927. https://doi.org/10.1093/nar/gku955
  11. Mostafavi S, Ray D, Warde-Farley D, Grouios C, Morris Q (2008) GeneMANIA: a real-time multiple association network integration algorithm for predicting gene function. Genome Biol 9:S4. https://doi.org/10.1186/gb-2008-9-s1-s4
  12. Ramalingam L, Menikdiwela K, LeMieux M, Dufour JM, Kaur G, Kalupahana N, Moustaid-Moussa N (2017) The renin angiotensin system, oxidative stress and mitochondrial function in obesity and insulin resistance. Biochim Biophys Acta Mol Basis Dis 1863:1106-1114. https://doi.org/10.1016/j.bbadis.2016.07.019
  13. Aleksunes LM, Manautou JE (2007) Emerging role of Nrf2 in protecting against hepatic and gastrointestinal disease. Toxicol Pathol 35:459-473. https://doi.org/10.1080/01926230701311344
  14. Wang G, Xiu P, Li F, Xin C, Li K (2014) Vitamin A supplementation alleviates extrahepatic cholestasis liver injury through Nrf2 activation. Oxid Med Cell Longev 2014:273692. https://doi.org/10.1155/2014/273692
  15. Kim DK, Kanai Y, Matsuo H, Kim JY, Chairoungdua A, Kobayashi Y, Enomoto A, Cha SH, Goya T, Endou H (2002) The human T-type amino acid transporter-1: characterization, gene organization, and chromosomal location. Genomics 79:95-103. https://doi.org/10.1006/geno.2001.6678
  16. Chung SY, Kao CH, Villarroya F, Chang HY, Chang HC, Hsiao SP, Liou G-G, Chen SL (2015) Bhlhe40 represses PGC-1α activity on metabolic gene promoters in myogenic cells. Mol Cell Biol 35:2518-2529. https://doi.org/10.1128/MCB.00387-15
  17. Erdel M, Weiskirchen R (1998) Assignment of CSRP1 encoding the LIM domain protein CRP1, to human chromosome 1q32 by fluorescence in situ hybridization. Cytogenet Cell Genet 83:10-11. https://doi.org/10.1159/000015152
  18. Liu L, Wang Q, Wang Q, Zhao X, Zhao P, Geng T, Gong D (2018) Role of miR29c in goose fatty liver is mediated by its target genes that are involved in energy homeostasis and cell growth. BMC Vet Res 14:325. https://doi.org/10.1186/s12917-018-1653-3
  19. Sierra-Ramos C, Velazquez-Garcia S, Vastola-Mascolo A, Hernandez G, Faresse N, de la Alvarez D (2020) SGK1 activation exacerbates diet-induced obesity, metabolic syndrome and hypertension. Endocrinology 244:149-162. https://doi.org/10.1530/JOE-19-0275
  20. Liang YJ, Jiang JG (2015) Characterization of malic enzyme and the regulation of its activity and metabolic engineering on lipid production. RSC Adv 5:45558-45570. https://doi.org/10.1039/C5RA04635A
  21. Lahey R, Carley AN, Wang X, Glass CE, Accola KD, Silvestry S, O'Donnell JM, Lewandowski ED (2018) Enhanced redox state and efficiency of glucose oxidation with miR based suppression of maladaptive NADPH-dependent malic enzyme 1 expression in hypertrophied hearts. Circ Res 122:836-845. https://doi.org/10.1161/CIRCRESAHA.118.312660
  22. Zhu BH, Zhang RH, Lv NN, Yang GP, Wang YS, Pan KH (2018) The role of malic enzyme on promoting total lipid and fatty acid production in phaeodactylum tricornutum. Front Plant Sci 9:826.https://doi.org/10.3389/fpls.2018.00826
  23. Sookoian S, Castano GO, Burgueno AL, Rosselli MS, Gianotti TF, Mallardi P, Martino JS, Pirola CJ (2010) Circulating levels and hepatic expression of molecular mediators of atherosclerosis in nonalcoholic fatty liver disease. Atherosclerosis 209:585-591. https://doi.org/10.1016/j.atherosclerosis.2009.10.011
  24. Haukeland JW, Damas JK, Konopski Z, Loberg EM, Haaland T, Goverud I, Torjesen PA, Birkeland K, Bjoro K, Aukrust P (2006) Systemic inflammation in nonalcoholic fatty liver disease is characterized by elevated levels of CCL2. Hepatology 44:1167-1174. https://doi.org/10.1016/j.jhep.2006.02.011
  25. Bansal S, Biswas G, Avadhani NG (2013) Mitochondria-targeted heme oxygenase-1 induces oxidative stress and mitochondrial dysfunction in macrophages, kidney fibroblasts and in chronic alcohol hepatotoxicity. Redox Biol 2:273-283. https://doi.org/10.1152/ajprenal.00160.2013
  26. Warskulat U, Borsch E, Reinehr R, Heller-Stilb B, Monnighof I, Buchczyk D, Donner M, Flogel U, Kappert G, Soboll S, Beer S, Pfefer K, Marschall H-U, Gabrielsen M, Amiry-Moghaddam M, Ottersen OP, Dienes HP, Haussinger D (2006) Chronic liver disease is triggered by taurine transporter knockout in the mouse. FASEB J 20:574-576. https://doi.org/10.1096/f.05-5016fje
  27. Banworth MJ, Li G (2018) Consequences of Rab GTPase dysfunction in genetic or acquired human diseases. Small GTPases 9:158-181. https://doi.org/10.1080/21541248.2017.1397833
  28. Chou HC, Chen CH, Lee HS, Lee CZ, Huang GT, Yang PM, Lee PH, Sheu JC (2007) Alterations of tumour suppressor gene PPP2R1B in hepatocellular carcinoma. Cancer Lett 253:138-143. https://doi.org/10.1016/j.canlet.2007.01.016
  29. Upadhyay A, Dixit U, Manvar D, Chaturvedi N, Pandey VN (2013) Afnity capture and identification of host cell factors associated with hepatitis C virus (+) strand subgenomic RNA. Mol Cell Proteomics 12:1539-1552. https://doi.org/10.1074/mcp.M112.017020
  30. Gu JG, Zhu Cl, Cheng DZ, Xie Y, Liu F, Zhou X (2011) Enchanced levels of apolipoprotein M during HBV infection feedback suppresses HBV replication. Lipids Health Dis 10:154. https://doi.org/10.1186/1476-511X-10-154
  31. Lubyova B, Hodek J, Zabransky A, Prouzova H, Hubalek M, Hirsch I, Weber J (2017) PRMT5: a novel regulator of hepatitis B virus replication and an arginine methylase of HBV core. PLoS ONE 12:e0186982. https://doi.org/10.1371/journal.pone.0186982
  32. Havis E, Duprez D (2020) EGR1 transcription factor is a multifaceted regulator of matrix production in tendons and other connective tissues. Int J Mol Sci 21:1664. https://doi.org/10.3390/ijms21051664
  33. Li TZ, Kim SM, Hur W, Choi JE, Kim J-H, Hong SW, Lee EB, Lee JH, Yoon SK (2017) Elk-3 contributes to the progression of liver fibrosis by regulating the epithelial-mesenchymal transition. Gut Liver 11:102-111. https://doi.org/10.5009/gnl15566
  34. Kostadinova RM, Nawrocki AR, Frey FJ, Frey BM (2005) Tumor necrosis factor alpha and phorbol 12-myristate-13-acetate downregulate human 11β-hydroxysteroid dehydrogenase type 2 through p50/p50 NF-κB homodimers and Egr-1. FASEB J 19:1-30. https://doi.org/10.1096/f.04-2820fje
  35. Escher G, Nawrocki A, Staub T, Vishwanath BS, Frey BM, Reichen J, Frey FJ (1998) Down-regulation of hepatic and renal 11β-hydroxysteroid dehydrogenase in rats with liver cirrhosis. Gastroenterology 114:175-184. https://doi.org/10.1016/S0016-5085(98)70645-6
  36. Rojo R, Raper A, Ozdemir DD, Lefevre L, Grabert K, Wollscheid-Lengeling E, Bradford B, Caruso M, Gazova I, Sanchez A, Lisowski ZM, Alves J, Molina-Gonzalez I, Davtyan H, Lodge RJ, Glover JD, Wallace R, Munro DAD, David E, Amit I, Miron VE, Priller J, Jenkins SJ, Hardingham GE, Blurton-Jones M, Mabbott NA, Summers KM, Hohenstein P, Hume DA, Pridans C (2019) Deletion of a Csf1r enhancer selectively impacts CSF1R expression and development of tissue macrophage populations. Nat Commun 10:3215. https://doi.org/10.1038/s41467-019-11053-8
  37. Katayama A, Nakatsuka A, Eguchi J, Murakami K, Teshigawara S, Kanzaki M, Nunoue T, Hida K, Wada N, Yasunaka T, Ikeda F, Takaki A, Yamamoto K, Kiyonari H, Makino H, Wada J (2015) Benefcial impact of Gpnmb and its significance as a biomarker in nonalcoholic steatohepatitis. Sci Rep 5:16920. https://doi.org/10.1038/srep16920
  38. Oishi Y, Hayashi S, Isagawa T, Oshima M, Iwama A, Shimba S, Okamura H, Manabe I (2017) Bmal1 regulates inflammatory responses in macrophages by modulating enhancer RNA transcription. Sci Rep 7:7086. https://doi.org/10.1038/s41598-017-07100-3
  39. Wu R, Zhang Y, Xiang Y, Tang Y, Cui F, Cao J, Zhou L, You Y, Duan L (2018) Association between serum S100A9 levels and liver necroinflammation in chronic hepatitis B. Transl Med 16:83. https://doi.org/10.1186/s12967-018-1462-2
  40. Teratani T, Tomita K, Furuhashi H, Sugihara N, Higashiyama M, Nishikawa M, Irie R, Takajo T, Wada A, Horiuchi K, Inaba K, Hanawa Y, Shibuya N, Okada Y, Kurihara C, Nishii S, Mizoguchi A, Hozumi H, Watanabe C, Komoto S, Nagao S, Yamamoto J, Miura S, Hokari R, Kanai T (2019) Lipoprotein lipase up-regulation in hepatic stellate cells exacerbates liver fibrosis in nonalcoholic steatohepatitis in mice. Hepatol Commun 3:1098-1112. https://doi.org/10.1002/hep4.1383
  41. Yang M, Nickels JT (2015) MOGAT2: a new therapeutic target for metabolic syndrome. Diseases 3:176-192. https://doi.org/10.3390/diseases3030176
  42. Villanueva-Paz M, Moran L, Lopez-Alcantara N, Freixo C, Andrade RJ, Lucena MI, Cubero FJ (2021) Oxidative stress in drug-induced liver injury (DILI): from mechanisms to biomarkers for use in clinical practice. Antioxidants 10:390. https://doi.org/10.3390/antiox10030390
  43. Iorga A, Dara L (2019) Chapter Two-cell death in drug-induced liver injury. In: Ramachandran A, Jaeschke H (eds) Advances in Pharmacology, vol 85. Academic Press, New York, pp 31-74. https://doi.org/10.1016/bs.apha.2019.01.006
  44. Low Y, Uehara T, Minowa Y, Yamada H, Ohno Y, Urushidani T, Sedykh A, Muratov E, Kuz'min V, Fourches D, Zhu H, Rusyn I, Tropsha A (2011) Predicting drug-induced hepatotoxicity using QSAR and toxicogenomics approaches. Chem Res Toxicol 24:1251-1262. https://doi.org/10.1021/tx200148a
  45. Chen X, Roberts R, Tong W, Liu Z (2021) Tox-GAN: an artifcial intelligence approach alternative to animal studies-a case study with toxicogenomics. Toxicol Sci. https://doi.org/10.1093/toxsci/kfab157